课题基金 / 基金详情

项目摘要

项目成果

Emanual M. Maverakis的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):Emanual Maverakis,医学博士,细胞免疫学家,接受过皮肤病学临床培训。该提案的一个目标是在Yoshikazu Takada博士的指导下,为他提供一段时间的分子生物学和生物化学指导培训,Yoshikazu Takada博士是一位专家生物化学家,以识别和表征几种整合素而闻名。马弗拉基斯博士的最终目标是成为一名独立的内科科学家。为了帮助这种转变,他将学习分子生物学和生物化学,同时表征纤维蛋白原片段的能力。C399tr抑制自身免疫。具体的假设是?C399tr将能够通过其结合整合素的能力抑制自身免疫。这个假设是基于以下观察。首先,在?C399tr中存在一个表征良好的MAC-1结合位点。(MAC-1是巨噬细胞和小胶质细胞表面的整合素)。其次,对接模拟研究已经确定整合素aV¿3和a4¿1是?C399tr的潜在靶点。第三,已知针对a4¿1整合素的抗体可以防止动物和人类的自身免疫。
英文摘要
DESCRIPTION (provided by applicant): Emanual Maverakis, M.D. is a cellular immunologist with clinical training in dermatology. One objective of this proposal is to provide him with a period of mentored training in molecular biology and biochemistry under the guidance of Dr. Yoshikazu Takada, an expert biochemist known best for identifying and characterizing several of the ¿1 integrins. Dr. Maverakis' ultimate goal is to develop into an independent physician scientist. To help with this transition, he will learn molecular biology and biochemistry while characterizing the ability of a fragment of fibrinogen, ?C399tr, to inhibit autoimmunity. The specific hypothesis is that ?C399tr will be able to inhibit autoimmunity through its ability to bind integrins. That hypothesis is based on the following observations. First, a well-characterized MAC-1 binding site exists within ?C399tr. (MAC-1 is an integrin on the surface of macrophages and microglia). Second, docking simulation studies have identified integrins aV¿3 and a4¿1 as potential targets for ?C399tr. Third, antibodies directed against a4¿1 integrin are known to prevent autoimmunity in animals and humans. The following are the proposal's specific aims. Specific Aim 1: Identify the integrins and cells bound by ?C399tr. Specific Aim 2: Identify ?C399tr's effect on the immune response. Specific Aim 3: Determine if ?C399tr is able to inhibit autoimmunity.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
A T cell-binding fragment of fibrinogen can prevent autoimmunity.
纤维蛋白原的 T 细胞结合片段可以预防自身免疫。
DOI: 10.1016/j.jaut.2009.11.017
发表时间: 2010
期刊: Journal of autoimmunity
影响因子: 12.8
作者: [Takada,Yoshikazu, Ono,Yoko, Saegusa,Jun, Sagusa,Jun, Mitsiades,Constantine, Mitsiades,Nicholas, Tsai,Jean, He,Yong, Maningding,Ernest, Coleman,Annie, Ramirez-Maverakis,Dalila, Rodrigues,Raphael, Rodriquez,Raphael, Takada,Yoko, Maverakis,Ema]
通讯作者: Maverakis,Ema
DOI: 10.1016/j.jaut.2009.11.011
发表时间: 2010-05
期刊: Journal of autoimmunity
影响因子: 12.8
作者: [Maverakis E, Miyamura Y, Bowen MP, Correa G, Ono Y, Goodarzi H]
通讯作者: Goodarzi H
Presentation of a determinant by MHC class II can be prevented through competitive capture by a flanking determinant on a multideterminant peptide.
通过多决定簇肽上的侧翼决定簇的竞争性捕获,可以防止 II 类 MHC 呈递决定簇。
DOI: 10.1016/j.jaut.2008.02.004
发表时间: 2008
期刊: Journal of autoimmunity
影响因子: 12.8
作者: [Maverakis,Emanual, Beech,JonathanT, Schneider,Susanne, Sercarz,EliE]
通讯作者: Sercarz,EliE
Stratedigm S100EON high-parameter flow cytometer to support multi-institutional research programs
  • 批准号:
    10431674
  • 项目类别:
  • 资助金额:
    $59.98万
  • 财政年份:
    2022
  • 负责人:
    Emanual M. Maverakis
  • 依托单位:
Mentoring Translational Scientists in Clinical Trial Immune Monitoring
  • 批准号:
    10359792
  • 项目类别:
  • 资助金额:
    $18.77万
  • 财政年份:
    2021
  • 负责人:
    Emanual M. Maverakis
  • 依托单位:
Mentoring Translational Scientists in Clinical Trial Immune Monitoring
  • 批准号:
    10670051
  • 项目类别:
  • 资助金额:
    $18.77万
  • 财政年份:
    2021
  • 负责人:
    Emanual M. Maverakis
  • 依托单位:
Investigation and Development of New Therapeutic Avenues for Scleroderma
  • 批准号:
    8792820
  • 项目类别:
  • 资助金额:
    $51.03万
  • 财政年份:
    2011
  • 负责人:
    Emanual M. Maverakis
  • 依托单位:
海外基金